Jaffetilchin Investment Partners LLC raised its position in shares of Johnson & Johnson (NYSE: JNJ – Get Rating) by 3.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,532 shares of the company stock after purchasing an additional 1,187 shares during the period. Jaffetilchin Investment Partners LLC’s holdings in Johnson & Johnson were worth $ 5,736,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Steward Financial Group LLC bought a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $ 34,000. Jackson Wealth Management LLC grew its holdings in Johnson & Johnson by 1.7% in the 3rd quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company stock valued at $ 40,000 after buying an additional 277 shares during the last quarter. Iron Horse Wealth Management LLC grew its holdings in Johnson & Johnson by 29.9% in the 4th quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company stock valued at $ 45,000 after buying an additional 61 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its holdings in Johnson & Johnson by 290.7% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company stock valued at $ 47,000 after buying an additional 218 shares during the last quarter. Finally, Gibson Wealth Advisors LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at approximately $ 49,000. 68.78% of the stock is owned by institutional investors.
Johnson & Johnson stock opened at $ 169.99 on Thursday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. The company has a market capitalization of $ 447.31 billion, a PE ratio of 22.91, a price-to-earnings-growth ratio of 3.41 and a beta of 0.66. Johnson & Johnson has a one year low of $ 155.72 and a one year high of $ 186.69. The business has a 50 day simple moving average of $ 178.59 and a 200 day simple moving average of $ 172.62.
Johnson & Johnson (NYSE: JNJ – Get Rating) last posted its earnings results on Tuesday, April 19th. The company reported $ 2.67 EPS for the quarter, topping the consensus estimate of $ 2.60 by $ 0.07. The business had revenue of $ 23.43 billion during the quarter, compared to the estimate consensus of $ 23.62 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. Johnson & Johnson’s revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the company earned $ 2.59 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.23 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th were given a dividend of $ 1.13 per share. This represents a $ 4.52 annualized dividend and a dividend yield of 2.66%. The ex-dividend date of this dividend was Monday, May 23rd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $ 1.06. Johnson & Johnson’s dividend payout ratio (DPR) is 60.92%.
In other news, insider William Hait sold 29,699 shares of the business’s stock in a transaction on Thursday, April 21st. The stock was sold at an average price of $ 183.58, for a total transaction of $ 5,452,142.42. Following the completion of the sale, the insider now owns 80,236 shares in the company, valued at $ 14,729,724.88. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $ 180.00, for a total value of $ 1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares of the company stock, valued at $ 2,785,140. The disclosure for this sale can be found here. In the last quarter, insiders sold 78,161 shares of company stock valued at $ 13,895,302. Corporate insiders own 0.35% of the company stock.
JNJ has been the topic of a number of research analyst reports. Citigroup lowered their target price on Johnson & Johnson from $ 210.00 to $ 205.00 in a report on Tuesday, May 17th. Morgan Stanley decreased their price objective on Johnson & Johnson from $ 175.00 to $ 173.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 6th. The Goldman Sachs Group lifted their price target on Johnson & Johnson from $ 163.00 to $ 181.00 and gave the stock a “neutral” rating in a report on Tuesday, April 12th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Finally, Credit Suisse Group lifted their price target on Johnson & Johnson from $ 200.00 to $ 205.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $ 190.50.
Johnson & Johnson Profile: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
Featured Stories:
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.
.